Moderna (MRNA) – PRNewswire
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
CARsgen Announced 2023 Annual Results
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
-
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
-
Flagship Pioneering Debuts Enabling Technologies Initiative
-
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
-
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
-
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
-
Flagship Pioneering Launches Pioneering Intelligence
-
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
-
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
-
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
-
Flagship Pioneering Named to Fortune's 2023 "Change the World" List
-
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
-
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
-
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner
-
CARsgen Announced 2023 Interim Results
-
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
-
UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings
-
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines
-
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
-
Flagship Pioneering Announces Appointment of Margo Georgiadis as CEO-Partner
-
UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022
-
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
-
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
-
Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and Moderna
-
Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
-
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments
-
Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy
-
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
-
Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months
-
Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
-
Direxion Launches mRNA ETF (MSGR)
-
Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters
-
Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development
-
Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine
-
Pioneering Medicines, An Initiative Of Flagship Pioneering, Establishes First-Of-Its-Kind Partnership With The Cystic Fibrosis Foundation To Develop Breakthrough Treatments For CF
-
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
-
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
-
Azzur Group and Moderna Expand Their Ongoing Relationship
-
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
-
Moderna Set to Join S&P 500
Back to MRNA Stock Lookup
